Claims:

1) A composition comprising a liposome or lipid complex and an entrapped active platinum compound, the liposome or lipid complex containing one or more lipids, wherein the active platinum compound to lipid ratio is from 1:50 to 1:2 by weight.

2) The composition of claim 1, wherein the active platinum compound to lipid ratio is from 1:50 to 1:5 by weight.

3) The composition of claim 1, wherein the active platinum compound to lipid ratio is from 1:50 to 1:10 by weight.

4) The composition of claim 1, wherein the active platinum compound is cisplatin.

5) The composition of claim 1, wherein the active platinum compound to lipid ratio is from 1:25 to 1:15 by weight.

6) The composition of claim 5, wherein the active platinum compound is cisplatin.

7) The composition of claim 6, the one or more lipids comprise DPPC.

8) The composition of claim 7, the one or more lipids comprise cholesterol.

9) The composition of claim 7, the one or more lipids comprise 50-100 **[90?]** mol% DPPC and 0-50 mol% cholesterol.

10) The composition of claim 7, the one or more lipids comprise 50-65 mol% DPPC and 35-50 mol% cholesterol.

11) A process for making a platinum aggregate comprising the steps of:

(a) combining an active platinum compound and a hydrophobic matrix carrying system;

(b) establishing the mixture at a first temperature; and

(c) thereafter establishing the mixture at a second temperature, which second temperature is cooler than the first temperature;

wherein the steps (b) and (c) are effective to increase the encapsulation of active platinum compound.

12) The process of claim 11, further comprising sequentially repeating the steps (b) and (c) for a total of two or more cycles.

13) The process of claim 11, wherein the active platinum compound solution is produced by dissolving active platinum compound in a saline solution to form a platinum solution.

14) The process of claim 13, wherein the active platinum compound is cisplatin

15) The process of claim 11, wherein the hydrophobic matrix carrying system comprises liposome or lipid complex-forming lipids.

16) The process of claim 15, wherein the one or more lipids comprise DPPC.

17) The process of claim 15, wherein the one or more lipids further comprise cholesterol.

18) The process of claim 11, wherein the hydrophobic matrix carrying system is produced by dissolving one or more lipids in ethanol to form a lipid solution and injecting the lipid solution into an aqueous medium containing active platinum compound.

19) The process of claim 11, further comprising sequentially repeating the steps (b) and (c) for a total of three or more cycles.

20) The process of claim 19, wherein the step (c) comprises establishing the mixture at a temperature from -25 degrees Celsius to 25 degrees Celsius.

21) The process of claim 19, wherein step (c) comprises establishing the mixture at a temperature from -5 degree Celsius to 5 degrees Celsius.

22) The process of claim 19, wherein the step (b) comprises establishing the mixture at a temperature from 4 degrees Celsius to 75 degrees Celsius.

23) The process of claim 19, wherein the step (b) comprises establishing the mixture at a temperature from 45 degrees Celsius to 55 degrees Celsius.

24) The process of claim 11, wherein the temperature differential between steps (b) and (c) is 25 degrees Celsius or more.

25) The process of claim 24, wherein the temperature established in step (b) is 50 degrees Celsius or more.

26) The process of claim 11, wherein the temperature established in step (b) is 50 degrees Celsius or more.

27) A platinum aggregate produced by the method of claim 11.

28) A platinum aggregate produced by the method of claim 14.

29) A pharmaceutical formulation comprising the composition of claim 1 and a pharmaceutically acceptable carrier or diluent.

30) A pharmaceutical formulation comprising the composition of claim 1, adapted for inhalation by a patient.

31) A pharmaceutical formulation comprising the composition of claim 1, adapted for injection into a patient.

32) The process of claim 11, further comprising, after all of steps (b) and steps (c) have been completed:

(d) removing un-entrapped active platinum compound by filtering through a membrane having a molecular weight cut-off selected to retain desired liposomes or lipid complexes and adding a liposome or lipid complex compatible liquid to wash out un-entrapped active platinum compound.